Mike Gladstone, global president and general manager of Pfizer Inflammation and Immunology unit, said that the acquisition of Arena is in line with the company’s capabilities and expertise in immunology and inflammatory-related conditions. Over the years, Pfizer has successfully created an innovation engine that develops potential medicines for patients worldwide with chronic and debilitating immuno-inflammatory conditions. The company understands that there is an urgent need to look into other treatment options with high potential, which is where Arena’s cannabinoid-drug pipeline comes in.
Germany has received nearly 900 applications for cannabis cultivation associations, but only just over half…
A Senate stopgap funding bill would delay the federal prohibition on most hemp-derived THC products…
He smokes in boardrooms, but he’s still on that underground frequency. This content originally appeared…
Fox News opinion ran a piece recently from Scott Chipman, vice president of Americans Against…
For our 50th anniversary, we handed the plant to the artists making its most striking…
Corporate valuation increased in 21 of the 38 states studied following medical marijuana legalization. Gross…